257523 Patient-level record de-duplication for immunization information systems and disease registries: Old problems with new solutions

Monday, October 29, 2012

Frederic Grant IV, PhD, MPH, PMP , Public Health Division, Northrop Grumman Corporation, Atlanta, GA
Jennifer Wain, IIS Program Manager , Public Health Division, Northrop Grumman Corporation, Atlanta, GA
Immunization Information Systems (IIS) and disease registries are at the leading edge of health record data exchanges and data interoperability. The American Recovery and Reinvestment Act (ARRA) appropriated funds to the HITECH Act to advance the technologies needed to support state and national program. The nature, volume, and importance of these data are placing demands of systems to be able to exactly identify patients. Additionally, records originating from different systems need to be managed in such a way to reduce data duplication and errors. During, 2011-12, CDC constituted and expert panel to specifically address the problem of patient-level record de-duplication. This panel conducted a patient-level record de-duplication national practice assessment. This session provides a summary of the results from this national survey along with a discussion of important implications for public health technology selection and support including SOAP, HL7, Master Patient Indexes, and integrating IIS into HIE and NHIN operations.

Learning Areas:
Public health or related laws, regulations, standards, or guidelines
Systems thinking models (conceptual and theoretical models), applications related to public health

Learning Objectives:
List and explain the top three problems in patient-level record de-duplication that impact public health.

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: Dr. Frederic (Fred) Grant is the Chief Scientist of Northrop Grumman Corporation’s Public Health Division—which provides advanced IT and business solutions for government and commercial clients including the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Department of Homeland Security (DHS), the National Institute of Health (NIH), the Substance Abuse and Mental Health Services Administration (SAMHSA), and the United States Agency for International Development (USAID).
Any relevant financial relationships? Yes

Name of Organization Clinical/Research Area Type of relationship
Northrop Grumman N/A Employment (includes retainer)

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.